Study of Cardonilizumab with Chemoradiotherapy and Optional Surgery for Locally Advanced Esophageal Squamous Cell Cancer

What this Trial Is About

Researchers are evaluating a new treatment approach for patients with locally advanced esophageal squamous cell carcinoma ESCC, a type of esophageal cancer with a poor prognosis. This prospective Phase II trial aims to observe the effectiveness and safety of combining cardonilizumab immunotherapy with chemoradiotherapy. The study is sponsored by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, and focuses on improving outcomes for patients through multimodal treatment strategies. Participants will receive two cycles of induction therapy combining cardonilizumab with chemotherapy drugs nab-paclitaxel and cisplatin. This is followed by concurrent chemoradiotherapy involving additional cycles of chemotherapy alongside radiotherapy doses of 50 to 50.4 Gy. After clinical evaluation, some patients may undergo surgery if deemed feasible. For patients who cannot have surgery or refuse it, cardonilizumab treatment may continue for up to two years or until disease progression. During the study, participants will undergo evaluations including imaging and clinical assessments to monitor their response to treatment. Researchers will measure outcomes such as event-free survival at one year, overall survival, adverse events, and rates of cancer recurrence or spread. The study includes regular blood tests and organ function monitoring to assess safety. Participants will be followed for at least one year to gather comprehensive data on treatment impact and tolerability.

Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer